March 7- Indian drug maker Ranbaxy Laboratories Ltd has recalled more than 64,000 bottles of the generic versions of its cholesterol-lowering drug in the United States due to reports of a dose mix-up, U.S. regulators said. Ranbaxy could not be reached for comment outside of India's business hours.» Read More
New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.
InterMune president & CEO Dan Welch says positive drug trial results bring hope to patients with idiopathic pulmonary fibrosis, and discusses the volatility in its stock.
CNBC's Morgan Brennan reports the pharmaceutical companies are developing oral therapies for the condition that could replace current treatments.
Feb 25- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. Bristol-Myers said the FDA had asked it to conduct seven post-marketing studies on Myalept. The drugmaker had co-developed the drug with AstraZeneca.
The suspension at the Toansa and Dewas plants, already banned by the U.S. Food and Drug Administration from shipping products to the United States, Ranbaxy's biggest market, will hit supplies to other key markets such as Europe and India, two people with direct knowledge of the matter said.
Feb 24- Pfizer Inc said on Monday that Prevnar 13, its blockbuster vaccine against childhood infections, prevented pneumonia outside of hospitals in people age 65 and older, in one of the largest drug trials ever conducted.
As one example, the FDA has sought to lower the dosage of painkiller acetaminophen from 500 milligrams in widely used products such as "extra strength" Tylenol to 325 mg, based on current knowledge of the liver damage the drug can cause.
WASHINGTON, Feb 21- The U.S. Food and Drug Administration is proposing sweeping changes to its 40- year-old system for approving over-the-counter drugs to make it quickly adaptable to scientific changes. The FDA has scheduled a hearing for public comments on March 25 and March 26.
Feb 21- Ariad Pharmaceuticals Inc, which has been struggling with safety concerns involving its only approved drug, said it agreed to add two directors backed by its second-largest investor Sarissa Capital Management to its board.
Feb 19- Furiex Pharmaceuticals Inc, which is developing a drug for irritable bowel syndrome, has put itself up for sale, Bloomberg reported on Wednesday, citing people with knowledge of the matter. The company was working with Bank of America Corp and has started contacting companies to gauge their interest in a potential deal, according to the report.
Feb 19- Furiex Pharmaceuticals Inc, which is developing a drug for irritable bowel syndromes, has put itself up for sale, Bloomberg reported on Wednesday, citing people with knowledge of the matter. The company was working with Bank of America Corp and has started contacting companies to gauge their interest in a potential deal, according to the report.
*Teva, Ranbaxy to pay $150,000 each to settle with New York State. Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition.
Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition. Teva and Ranbaxy will pay the New York state $300,000 and have agreed to refrain from similar agreements in the future.
Feb 18- After a nearly three-year campaign at Forest Laboratories Inc that spanned two proxy battles and the ousting of a chief executive, billionaire activist investor Carl Icahn has once again ended up on top.
*Forest Labs shares soar; Actavis agrees to buy company. NEW YORK, Feb 18- The S&P 500 and Nasdaq rose on Tuesday, following Wall Street's biggest weekly gain of the year, as merger activity increased confidence that there is value in the stock market even as the benchmark index nears a record high.
*Forest Labs shares jump, Actavis to purchase. NEW YORK, Feb 18- U.S. stocks edged up on Tuesday, following Wall Street's biggest gain of the year, as merger activity boosted confidence there is still value in the market even as the S&P 500 nears a record high.
Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.
Feb 18- Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, expanding its portfolio of specialty pharmaceuticals for neurological and other disorders. Actavis said it would pay the equivalent of $89.48 per share, representing a premium of 25 percent to Forest's closing price on Friday.
*FDA chief says important for India to work with foreign regulators. MUMBAI, Feb 18- The head of the U.S. Food and Drug Administration called for more collaboration among regulators to improve drug quality and safety as she wrapped up a visit to India after recent import bans on drugs from a handful of plants in the country.
MUMBAI, Feb 18- The U.S. Food and Drug Administration is working with Indian regulators to enhance the quality and safety of drugs made there, the FDA's Commissioner Margaret Hamburg said on Tuesday.